

1. A method for increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery in a human mammal which comprises the step of co-administering effective amounts of tissue plasminogen activator (tPA) and anti-CD18 antibody to the mammal wherein neither the tPA nor the anti-CD18 antibody is administered to the mammal until about three to five hours after the onset of focal ischemic stroke.

2. The method of claim 1 that increases cerebral blood flow and reduces infarct size in the mammal.

3. The method of claim 1 wherein the anti-CD18 antibody is an antibody fragment.

4. The method of claim 3 wherein the anti-CD18 antibody fragment is a F(ab')<sub>2</sub>.

5. The method of claim 1 wherein the anti-CD18 antibody is humanized.

6. The method of claim 1 wherein the anti-CD18 antibody is administered to the mammal by bolus dosage.

7. The method of claim 1 wherein the anti-CD18 antibody is administered intravenously.

8. The method of claim 1 wherein the anti-CD18 antibody is administered via continuous infusion.

9. The method of claim 1 wherein the anti-CD18 antibody and the tPA are simultaneously administered to the mammal.

10. The method of claim 1 wherein the anti-CD18 antibody is administered before the tPA is administered to the mammal.

11. The method of claim 1 wherein the anti-CD18 antibody is humanized H52 antibody comprising heavy chain sequence of SEQ ID NO:10 and light chain sequence of SEQ ID NO:11.

12. The method of claim 11 wherein the H52 antibody is a F(ab')<sub>2</sub>.

13. The method of claim 1, wherein the anti-CD18 antibody binds to an extracellular domain of CD18 and inhibits or reduces the ability of a cell expressing CD18 to bind to endothelium.

14. The method of claim 1, wherein the anti-CD18 antibody binds CD18 with an affinity of 4 nm or less.

15. The method of claim 1, wherein the anti-CD18 antibody binds CD18 with an affinity of 3 nm or less.

16. The method of claim 1, wherein the anti-CD18 antibody binds CD18 with an affinity of 1 nm or less.

17. The method of claim 1, wherein the anti-CD18 antibody dissociates the CD11b/CD18 complex.

18. The method of claim 1, wherein the anti-CD18 antibody binds to the epitope bound by H52 antibody.